Takeda Pharmaceutical Co. Ltd. hit a number of milestones as it reported results for the fiscal year ended 31 March, exceeding JPY4tn ($29.74bn) in revenue and logging a record core operating profit of nearly JPY1.2tn, while moving into a new “post-Shire” phase of capital allocation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?